Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health PD-1/PD-L1 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 6304-D

    Medicare Part B PD-1/PD-L1 Step Therapy for Basal Cell Carcinoma and Squamous Cell Carcinoma

    Customize your policy alerts

    Sign up for zing_health Policy 6304-D alerts

    Get alerted when Policy 6304-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of specified PD-1/PD-L1 products for members receiving treatment for basal cell carcinoma or squamous cell carcinoma. Libtayo is preferred, while coverage of non-preferred Keytruda requires an applicable clinical exception through prior authorization.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B PD-1/PD-L1 Step Therapy for Basal Cell Carcinoma and Squamous Cell Carcinoma
    Policy CodePolicy 6304-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument either treatment with the requested non-preferred product within the past 365 days or an intolerable adverse event with the preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Preferred product
    1Non-preferred product
    365 daysPrior-treatment lookback
    2Exception pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-Preferred Product Exception Criteria

    Non-preferred product exception criteria

    Coverage for a non-preferred product is provided when either of the following criteria is met.

    Non-preferred product coverage exception

    • Recent prior use: Member has received treatment with the non-preferred product in the past 365 days.within the past 365 days
    • Intolerable adverse event: Member has a documented intolerable adverse event with the preferred product.documented intolerable adverse event

    Initial Non-Preferred Product Coverage

    Initial non-preferred product coverage

    Coverage for a non-preferred product is provided when either criterion is met.

    Initial non-preferred product exception

    • Prior treatment with requested product: Member has received treatment with the non-preferred product in the past 365 days.past 365 days
    • Intolerance to preferred product: Member has a documented intolerable adverse event with the preferred product.documented intolerable adverse event

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required for Non-Preferred Products

    Obtain prior authorization for all treatment requests involving a non-preferred PD1/PDL1 product. Zing Health reviews the request for clinical circumstances that exclude use of the preferred product; coverage may be based on prior product use and is subject to applicable NCD, LCD, and Medicare Part B utilization-management requirements.

    • Applies to all members requesting treatment with a non-preferred product.
    • The exception review determines whether a clinical exception to the preferred-product requirement can be made.
    • Affected products are used for basal cell carcinoma and squamous cell carcinoma.
    Prior Authorization

    Preferred Product Review May Still Apply

    Preferred products may still require clinical prior authorization review. Verify authorization requirements before treatment, even when requesting the plan’s preferred product, Libtayo (cemiplimab).

    • Preferred product: Libtayo (cemiplimab).

    Product Preference and Exception Pathways

    StepNon-preferred productCoverage exception requirementLookback period
    1Keytruda (pembrolizumab)Either documented treatment with Keytruda or a documented intolerable adverse event with preferred Libtayo (cemiplimab)Past 365 days for prior Keytruda treatment

    Policy Scope and Product Preference

    This policy addresses Medicare Part B PD-1/PD-L1 products used for members receiving treatment for basal cell carcinoma or squamous cell carcinoma. The plan identifies Libtayo (cemiplimab) as the preferred product and Keytruda (pembrolizumab) as the non-preferred product. Non-preferred product coverage is available through a clinical exception process and prior authorization; step therapy operates in addition to applicable Medicare coverage determinations and utilization management programs.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B PD-1/PD-L1 Step Therapy for Basal Cell Carcinoma and Squamous Cell Carcinoma
    Policy CodePolicy 6304-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument either treatment with the requested non-preferred product within the past 365 days or an intolerable adverse event with the preferred product.
    SourceLink
    On This Page
    Non-Preferred Product Exception CriteriaInitial Non-Preferred Product CoverageAuthorization and Documentation RequirementsProduct Preference and Exception PathwaysPolicy Scope and Product Preference
    Step Therapy

    Non-Preferred Product Step Therapy

    For a non-preferred product, document that the member either received treatment with that product within the prior 365 days or has a documented intolerable adverse event with the preferred product.

    • The 365-day prior-treatment requirement applies to treatment with the non-preferred product.
    • An intolerable adverse event with the preferred product is an alternative exception pathway.
    Documentation Required

    Clinical Exception Documentation

    Submit clinical documentation supporting the applicable exception criterion: records confirming treatment with the non-preferred product during the past 365 days, or documentation of an intolerable adverse event associated with the preferred product.

    • Document the product, treatment date or dates, and relevant clinical details for prior non-preferred treatment.
    • For an adverse event, document the event, its relationship to the preferred product, and why it was intolerable.
    Denial Risk

    Exception Criteria Not Met

    A non-preferred product may be denied when the member has not received that product within the past 365 days and there is no documented intolerable adverse event with the preferred product. Submit complete records to support the exception request.

    • Denial risk applies when neither exception criterion is satisfied.
    • Coverage remains subject to applicable NCD, LCD, and Medicare Part B utilization-management programs.